pyridine/悪性腫瘍

BACKGROUND OF THE INVENTION Despite scientific advances in understanding the causes and treatment of human malignancy, a persistent challenge facing basic and clinical investigators is how to adequately treat primary and metastatic brain tumors. The blood-brain barrier is a physiologic obstruction

FIELD OF THE INVENTION The invention relates to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines that are useful for treating pancreatic cancer and other types of cancers that are associated with aberrant expression of Hedgehog proteins. BACKGROUND OF THE INVENTION Pancreatic cancer is the fourth most

FIELD OF THE INVENTION The invention relates to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines that are useful for treating pancreatic cancer and other types of cancers that are associated with aberrant expression of Hedgehog proteins. BACKGROUND OF THE INVENTION Pancreatic cancer is the fourth most

FIELD OF THE INVENTION The invention relates to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines that are useful for treating pancreatic cancer and other types of cancers that are associated with aberrant expression of Hedgehog proteins. BACKGROUND OF THE INVENTION Pancreatic cancer is the fourth most

FIELD OF THE INVENTION This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer. BACKGROUND OF THE INVENTION Protein kinases represent a large family of proteins which play a central role in the regulation of a

BACKGROUND OF THE INVENTION The efficacy of any cancer chemotherapy is limited by the sensitivity of specific cancers to a particular treatment. Even when a cancer is responsive to a particular chemotherapy, acute and chronic toxic effects associated with the chemotherapy often force a reduction in

FIELD OF THE INVENTION This invention relates to the manufacture of novel chemical compounds which have biological activity, particularly to novel chemical compounds that are cytotoxic against colon cancer cells and colon cancer cell lines. BACKGROUND OF THE INVENTION Cancer is considered to be the

FIELD OF THE INVENTION The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. SUMMARY OF THE INVENTION According to a first aspect of the invention

BACKGROUND Field The present disclosure relates to new substituted pyrrolopyridine and pyrrolopyrazine compounds and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulation of TAK activity in a human or animal subject are also provided for the

BACKGROUND OF THE INVENTION The efficacy of any cancer chemotherapy is limited by the sensitivity of specific cancers to a particular treatment. Even when a cancer is responsive to a particular chemotherapy, acute and chronic toxic effects associated with the chemotherapy often force a reduction in

FIELD OF THE INVENTION The present invention relates to crystalline forms of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-- 3-yl}phenyl)-N'-(3-fluorophenyl)urea, processes for preparing the crystalline forms, pharmaceutical formulations thereof, and methods of treating

TECHNICAL FIELD The present invention relates to a fused heterocycle derivative and use thereof. More particularly, the present invention relates to a compound having a strong Smo inhibitory activity and useful for the prophylaxis or treatment of cancer and the like, and use thereof. BACKGROUND OF

CROSS REFERENCE TO RELATED APPLICATIONS This application is a national stage of PCT Application No. PCT/EP2014/058361, filed Apr. 24, 2014, which claims priority for EPO Patent Application No. 13165167.1, filed Apr. 24, 2013 and EPO Patent Application No. 13186116.3, filed Sep. 26, 2013, all of

BACKGROUND OF THE INVENTION The present invention relates to a novel compound, compositions containing the compound, the use of the compound in inhibiting the growth of malignant neoplasms in mammals, and a method of preparing the compound. A number of chemicals that inhibit the growth or otherwise

FIELD OF THE INVENTION The cyclin-dependent kinase (CDK) complexes are well-conserved Ser/Thr kinase family, and it has been shown to be activated by the binding of regulatory partner, generally a cyclin. There are total 20 CDK family members and 5 CDK-like proteins based on the similarities in